


## References

(A)

- 1) **Aggarwal, H.; Saxena, A.;Lubana ,PS.; Mathur ,RK and Jain ,DK.(2008):** Treatment of keloids and hypertrophic scars using bleomycin. J. Cosmet. Dermatol ;7:43-9.
- 2) **Alan, D. and Ian, A. (2000):** Hypertrophic scars and keloids. In Charles I (ed) Fundamental Techniques of Plastic Surgery and Their Surgical Applications. 10<sup>th</sup> eds. Harcourtpublishers limited P. 127.
- 3) **Alster, T.S. and Tanzi, E.L. (2003):** Hypertrophic scars and keloids: Etiology and management. Am. J. Clin. Dermatol, 4(4):235.
- 4) **Ardehali, B.; Nouraei ,SA.; van Dam,H.; Dex ,E.; Wood, S and Nduka ,C.(2007):** Objective assessment of keloid scars with three-dimensional imaging: Quantifying response to intralesional steroid therapy. Plast. Reconstr. Surg. ;119:556-61.
- 5) **Atiyeh BS. (2007):** Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic.Plast. Surg. 31:468–94.

## (B)

- 6) **Bartkova, J.; Grøn, B.; Dabelsteen, E. and Bartek, J. (2003):** Cell-cycle regulatory proteins in human wound healing. Archives of Oral Biology, 48(2): 125-132.
- 7) **Baryza, M.J. and Baryza, G.A. (1995):** The Vancouver scar scale: An administration tool and its interpreter reliability. J. Burn Care Rehabil, 16: 535.
- 8) **Baselt, R. (2008).** Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, California, pp. 1637-1639.
- 9) **Bayat, A.; McGrouther, D.A. and Ferguson, M. (2003):** Skin scarring. B.M.J; 326(7380): 326 : 88-92.
- 10) **Beausang, E.; Floyd, H.; Dunn, K.W.; et al. (1998):** A new quantitative scale for clinical scar assessment. Plast Reconstr Surg, 102 (6): 1954.
- 11) **Bellamy, WT. (1996):** "P-glycoproteins and multidrug resistance". Annu Rev Pharmacol Toxicol 36: 161–83.
- 12) **Berman, B and Flores, F. (1998):** The treatment of hypertrophic scars and keloids. Eur. J. Dermatol.;8:591–5.
- 13) **Berman, B, Perez.; OA, Konda.; S, Kohut ,BE.; Viera, MH and Delgado, S .(2007):** A review of the biologic effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol. Surg. ;33:1291-302.

- 14) **Bischof, M.; Krempien, R.; Debus, J and Treiber, M.(2007):** Postoperative electron beam radiotherapy for keloids: Objective findings and patient satisfaction in self-assessment. Int. J. Dermatol. 2007;46:971-5.
  - 15) **Breitkreutz, D.; Mirancea, N. and Nischt, R.( 2009):** Basement membranes in skin: unique matrix structures with diverse functions? Histochem. Cell Biol. 132, 1–10.
  - 16) **Brockes, J.P.; Kumar, A. and Vellaoso, C.P. (2001):** Regeneration as an evolutionary variable. J Anat;199 (pt 1-2): 3.
  - 17) **Bruce, M.C. (1994):** Integumentary, skeletal and muscular systems .In Bruce M (ed). Human Embryology and Developmental Biology. 1<sup>st</sup> eds. Mosby-Year Book, Library of Congress.Hoffmann press, pp.140.
  - 18) **Burd, A and Huang, L.(2005):** Hypertrophic response and keloid diathesis: two very different forms of scar. Plast. Reconstr .Surg. ;116:150-157.
- 
- 19) **Canyo, FM.; Tanaka .; V and Messina, MC.(2009):** Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg ;35:629-33.
  - 20) **Ceilly, R. (1987):** The treatment of hypertrophic scars and keloids. In: Ebstein E (ed) Skin Surgery. 6<sup>th</sup> eds. WE Saunders Co. Philadelphia, pp.580.

- 21) **Chang, H.Y.; Sneddon, J.B.; Alizadeh, A.A.; Sood, R.; West, R.B.; Montgomery, K.; Chi, J.T.; van de Rijn, M.; Botstein, D. and Brown, P.O. (2004):** Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. *PLoS Biol*, 2(2):E7.
- 22) **Chowdri , NA.; Masarat, M.; Mattoo A and Darzi MA.(1999):** Keloids and hypertrophic scars: Results with intraoperative and serial postoperative corticosteroid injection therapy. *Aust. N.Z.J. Surg.* ;69:655-9.
- 23) **Copcu, E.; Sivirioglu, N. and Oztan, Y. (2004):** Combination of surgery and intralesional verapamil injection in the treatment of keloid .*J. Burn Care Rehabil*, 25:1-7.
- 24) **Cosman, B.; Crikelain, G.; Caulin, J.; et al. (1991):** The surgical treatment of keloids. *Plast Reconstr Surg*, 27: 335.
- 25) **Cribier, B and Chilblain.(2001):** *Ann Dermatol Venereol.* Apr;128(4):557-60.

## (D)

- 26) **D'Andrea, F.; Brongo, S.; Ferraro, G. and Baroni, A. (2002):** Prevention and treatment of keloids with intralesional verapamil. *Dermatology*, 204:60-2.
- 27) **Daley, J.M., Brancato, S.K., Thomay, A.A., Reichner, J.S and Albina, J.E.( 2010):** The pheno- type of murine wound macrophages. *J. Leukoc. Biol.* 87, 59–67 .
- 28) **Darougheh, A.;Asilian, A and Shariati, F.(2009)** Intralesional triamcinolone alone or in combination with 5-fluorouracil for the

- treatment of keloid and hypertrophic scars. Clin Exp Dermatol ; 34:219-23.
- 29) **Datubo-Brown, D.D. (1990):** Keloids: a review of the literature. Br. J. Plast Surg, 43: 70.
- 30) **Davies, DM.(1985):** Scars, hypertrophic scars and keloids. Br. Med. J .;290:1056-8.
- 31) **Davison ,SP.; Dayan,JH.; Clemens, MW.;Sonni, S.; Wang, A and Crane ,A.(2009):** Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Surg J ;29:40-6.
- 32) **Davison ,SP.; Mess ,S.; Kauffman ,LC and Al-Attar ,A.(2006):** Ineffective treatment of keloids with interferon alpha-2b. Plast. Reconstr. Surg. ;117:247-52.
- 33) **de la Torre, J. and Sholar A. (2006):** Wound healing: Chronic wounds. Growth factors; phases of wound healing, eMedicine Plastic Surg. 457, pp. 3–6 .
- 34) **de Oliveira, GV.; Nunes, TA.; Magna, LA.; Cintra, ML.; Kitten, GT and Zarpellon ,S .(2001):** Silicone versus nonsilicone gel dressings: A controlled trial. Dermatol. Surg.;27:721-6.
- 35) **Desmouliere, A.; Chaponnier, C. and Gabbiani, G. (2005):** Tissue repair, contraction, and the myofibroblast. Wound Repair and Regeneration, 3(1):7-12.
- 36) **DiPietro, L.A. and Burns, A.L., Eds. (2003):** Wound Healing: methods and protocols. Methods in molecular medicine. Volume 90, Issue 9, page 1167.British Journal of Surgery.
- 37) **Doering, C.J and Zamponi, G.W.(2003):** Molecular pharmacology of high voltage-activated calcium channels, J. Bioenerg Biomembr. Dec;35(6):491-505.

- 38) **Dustan, H. (1992):** Growth factor and racial differences in severity of hypertension and diseases. *Lancet*, 339(30): 1339-40.

## (E)

- 39) **Eichler, M.J. and Carlson, M.A. (2005):** Modeling dermal granulation tissue with the linear fibroblast-populated collagen matrix: A comparison with the round matrix model. *Journal of Dermatological Science*, 41(2): 97-108.
- 40) **Eishi, K.; Bae, S.J.; Ogawa, F.; Hamasaki, Y.; Shimizu, K and Katayama, I. (2003):** Silicone gel sheets relieve pain and pruritus with clinical improvement of keloid: Possible target of mast cells. *J Dermatolog. Treat* ;14:248-52.
- 41) **Ellen Beck .; William, J .; Sieber and Raul Trejo. (2005):** "Management of Cluster Headaches". *American Family Physician* 71 (4): 717–724.
- 42) **Enoch, S. and Price, P. (2004):** Cellular, molecular and biochemical differences in the pathophysiology of healing between acute wounds, chronic wounds and wounds in the elderly.
- 43) **Espana, A., Solano, T and Quintanilla, E. (2001):** Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. *Dermatol Surg* ;27:23–7.
- 44) **Etscheid, M., Beer, N., and Dodt, J. (2005):** The hyaluronan-binding protease upregulates ERK1/2 and PI3K/Akt signalling pathways in fibroblasts and stimulates cell proliferation and migration. *Cellular*

Signalling,17(12):1486–1494.

## (F)

- 45) **Falanga, V. (2005):** Wound healing and its impairment in the diabetic foot. *Lancet*, 366(9498):1736-43.
- 46) **Fitzpatrick, R.E. (1999):** Treatment of inflamed hypertrophic scars using intralesional 5-FU. *Dermatol. Surg*, 25: 224-32.

## (G)

- 47) **Garg, H.G.; Thompson, B.T. and Hales, C.A. (2000):** Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. *Am. J. Physiol Lung Cell Mol Physiol*, 279(5):L779-89.
- 48) **George, F.M. (1990):** Histology of the skin. In David E, Rosalie E, Chrisitne J. and Bernett J. (eds). *Lever's Histopathology of the skin*. 8<sup>th</sup> eds. Vol(I). Lippincott Company, Philadelphia, Toronto, pp. 5.
- 49) **Gurtner, G.C., Werner, S., Barrandon, Y and Longaker, M.T. (2008):** Wound repair and regeneration. *Nature* 453, 314–321.

## (H)

- 50) **Har-Shai ,Y.; Brown, W.; Labbéé ,D.; Domp martin, A.; Goldine, I and Gil ,T. .(2008):** Intralesional cryosurgery for the treatment of

- hypertrophic scars and keloids following aesthetic surgery: The results of a prospective observational study. *Int. J. Low Extrem Wounds* ;7:169-75.
- 51) **Haurani, MJ.; Foreman ,K.; Yang, JJ and Siddiqui, A.(2009):** 5-Fluorouracil treatment of problematic scars. *Plast. Reconstr. Surg.* ;123:139-4.
- 52) **Heldin, C. and Westermarck, B. (1996):** Role of platelet-derived growth factor in vivo. In: Clark RAF (ed). *The Molecular and Cellular Biology of Wound Repair*, 2<sup>nd</sup> edn. London, Plenum Press, pp. 249.
- 53) **Hinz, B. (2005):** Masters and servants of the force: The role of matrix adhesions in myofibroblast force perception and transmission. *European Journal of Cell Biology*, 85(3-4): 175-181.
- 54) **Hosnuter, M.;Payasli, C.; Isikdemir, A and Tekerekoglu ,B.(2007):** The effects of onion extract on hypertrophic and keloid scars.*J.WoundCare*;16:251-4.



- 55) **Ioulios, P.; Charalampos, M. and Efrossini, T.(2003):** The spectrum of cutaneous reactions associated with calcium antagonists: a review of the literature and the possible etiopathogenic mechanisms.

## (J)

- 56) ***Jia, T and Pamer, E.G.( 2009):*** Immunology. Dispensable but not irrelevant.Science325,549–550.

## (K)

- 57) ***Kal, HB and Veen, RE.(2005):*** Biologically effective doses of postoperative radiotherapy in the prevention of keloids. Dose-effect relationship. Strahlenther Onkol ;181:717-23.
- 58) ***Kal ,HB.; Veen ,RE and Jürgenliemk-Schulz , IM.(2009):*** Dose-effect relationships for recurrence of keloid and pterygium after surgery and radiotherapy. Int J Radiat Oncol Biol Phys ;74:245-51.
- 59) ***Kealey, G.P.; Jensen, K.L and Laubenthal, K.N. (1990):*** Prospective randomized comparison of two types of pressure therapy garments. J. Burn Care Rehabil, 11: 334-6.
- 60) ***Kelly ,A.P. (2004):*** Medical and surgical therapies for keloids. Dermatol. Ther. 17:212–8.
- 61) ***Ketchum .LD.; Robinson, DW and Masters ,FW(1971):*** Follow-up on treatment of hypertrophic scars and keloids with triamcinolone. Plast .Reconstr. Surg. , 48:256-9.
- 62) ***Koc, E.; Arca, E.; Surucu ,B and Kurumlu, Z.(2008):*** An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and

- intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. *Dermatol Surg* ;34:1507-14.
- 63) **Kontochristopoulos ,G.; Stefanaki ,C.; Panagiotopoulos ,A.; Stefanaki ,K.; Argyrakos, T and Petridis ,A.(2005):** Intralesional 5-fluorouracil in the treatment of keloids: An open clinical and histopathologic study. *J. Am. Acad. Dermatol* ;52:474-9.
- 64) **Kose ,O and Waseem ,A. (2008) :**Keloids and hypertrophic scars: are they two different sides of the same coin? *Dermatol. Surg.* 34:336–46.
- 65) **Kuo ,YR.; Wu, WS.; Jeng, SF.; Nicolini ,J and Zubillaga, M. (2005):**Activation of ERK and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed-dye laser treatment. *Lasers Surg Med* ;36:31-7.

## (L)

- 66) **Lansdown, A.B.G.; Sampson, B. and Rowe, A. (2001):** Experimental observations in the rat on the influence of cadmium on skin wound repair. *International Journal of Experimental Pathology*, 82(1): 35-41.
- 67) **Larjava, H.; Koivisto, L.; and Hakkinen, L. (2002):** Chapter 3: Keratinocyte Interactions with Fibronectin During Wound Healing. In, Heino, J. and Kahari, V.M. *Cell Invasion. Medical Intelligence Unit* ; 33.
- 68) **Lawrence, VV.T. (1991):** In search of the optimal treatment of keloids: report of a series and a review of the literature. *Ann. Plast Surg*, 22: 164-78.

- 69) **Lee, JH.; Kim, SE and Lee, AY.(2008):** Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. *Int. J. Dermatol* ;47:183-6.
- 70) **Lee, RC. And Ping.JA.(1990):** Calcium antagonists retard extracellular matrix production in connective tissue equivalent. *J. Surg. Res.*49(5):463-466.
- 71) **Leineke, J.; Fenike, R.H and Yvonne, A.M. (2004):** The patient and observer scar assessment scale: A reliable and feasible tool for scar evaluation. *Plast Reconstr Surg*, 113(7): I960-5.
- 72) **Leventhal , D.; Furr, M and Reiter, D.(2006):** Treatment of keloids and hypertrophic scars. *Arch Facial Plast Surg*. 2006; 8(6):362-368.
- 73) **Lucas, T., Waisman, A., Ranjan, R., Roes, J., Krieg, T., Muller, W., Roers, A and Eming, S.A.(2010);** Differential roles of macrophages in diverse phases of skin repair. *J. Immunol*. 184, 3964–3977.



- 74) **Macdonald, K.P., Palmer, J.S., Cronau, S., Seppanen, E., Olver, S., Raffelt, N.C and Kuns, R. (2010):** An antibody against the colony-stimulating factor 1 receptor (CSF1R) depletes the resident subset of monocytes and tissue and tumor-associated macrophages but does not inhibit inflammation. *Blood*.
- 75) **Macintyre, L and Baird, M. (2006):** Pressure garments for use in the treatment of hypertrophic scars—a review of the problems associated with their use. *Burns*. 32:10–5.

- 76) **Mackie, R. (1992):** Soft tissue tumors. In: Mackie R, Burton I and Ebling F (eds). Textbook of Dermatology, 5<sup>th</sup> edn, Blackwell scientific publications, pp. 2073.
- 77) **Malhotra ,AK.;Gupta, S.; Khaitan, BK and Sharma, VK.(2007):** Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology ;215:63-5 .
- 78) **Manuskiatti, W and Fitzpatrick, RE.(2002):** Treatment response of keloidal and hypertrophic sternotomy scars: Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol ;138:1149-55.
- 79) **Margaret Shanthi,FX.;Ernest,K and Dhanraj, P.( 2008):** Comarison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J.Dermatol. Venereol. Leprol;74(4):343-348.
- 80) **Marneros,AG.;Norris,JE.;Olsen,BR and Reichenberger,E.(2001):** Clinical genetics of familial keloids. Arch.Dermatol.;137(11):1429-1434.
- 81) **Martin, P. and Leibovich, SJ. (2005):** Inflammatory cells during wound repair: the good, the bad and the ugly. Trends in Cell Biology, 15(11): 599-607.
- 82) **McGrath, J.A.; Eady, R.A. and Pop, P.M. (2004):** Anatomy and organization of human skin. In Tony B; Stephen B, Neil C and Christopher G (eds). Rook's Textbook Of Dermatology 7<sup>th</sup> eds. Blackwell Science Ltd, Oxford, pp. 31.
- 83) **Mercandetti, M. and Cohen, A.J. (2005):** Wound Healing: Healing and Repair. J. Wound Ostomy Continence Nurs. ; 32 (5): 317-320.
- 84) **Midwood, K.S.; Williams, L.V. and Schwarzbauer, J.E. (2004):**

- Tissue repair and the dynamics of the extracellular matrix. The International Journal of Biochemistry & Cell Biology, 36(6): 1031–1037.
- 85) **Mirastschijski, U.; Haaksma, C.J.; Tomasek, J.J. and Ågren, M.S. (2004):** Matrix metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, contraction and myofibroblast formation in skin wounds. Experimental Cell Research, 299(2): 465-475.
- 86) **Mirza, R., Dipietro, L.A and Koh, T.J.(2009):** Selective and specific macrophage ablation is detrimental to wound healing in mice. Am. J. Pathol. 175, 2454–2462.
- 87) **Moustafa, M.F.H. and Abdel-Fattah, A.F. (1975):** Presumptive evidence of the effect of pregnancy oestrogens on keloid growth. A case report, Plast Reconstr Surg, 56(4):450-3.
- 88) **Muneuchi, G.; Suzuki ,S.; Onodera ,M.; Ito ,O, Hata, Y and Igawa, HH.(2006);** Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg Hand Surg ;40:111-6.
- 89) **Mustoe, T.A.; Cooter, R.D.; Gold, M.H.; et al. (2002):** International clinical recommendations on scar management. Plast Reconstr Surg, 110 (2): 560-71.
- 90) **Mustoe ,T.A.( 2008):**Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg ;32:82-92.
- 91) **Mutalik, S. (2005):**Treatment of keloids and hypertrophic scars. Indian J. Dermatol Venereal Leprol, 71:3.



- 92) **Naeini ,FF.; Najafian, J and Ahmadpour K. (2006):** Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. *Dermatol. Surg.* 32:1023–30.
- 93) **Nanda, S and Reddy ,BS.(2004):** Intralesional 5-fluorouracil as a treatment modality of keloids. *Dermatol Surg* ;30:54-6.
- 94) **Nedelec, B.; Shankowsky, H.A. and Tredget, E.E. (2000):** Rating the resolving hypertrophic scar: comparison of the Vancouver scar scale and scar volume. *J. Burn Care Rehabil*, 21: 205-12.
- 95) **Neely, AN.; et al. (1999):** Gelatinase activity in keloids and hypertrophic scars. *Wound Repair Regen.* 7:166–71.
- 96) **Nelson,E.;Patricia Guhring and John,P.(2007):** Intralesional verapamil prevents progression of peyronie,s disease.*J.Impot.Res.* 69(6) 1181-1183.
- 97) **Nguyen, D.T.; Orgill, D.P. and Murphy, G.F. (2009):** Chapter 4: The Pathophysiologic Basis for Wound Healing and Cutaneous Regeneration. *Biomaterials For Treating Skin Loss.* CRC Press (US) & Woodhead Publishing (UK/Europe), Boca Raton/ Cambridge, p. 25-57. **Nicoli, J.; Bos, M. and Smale, G. (1997):** A protocol for the treatment of hypertrophic scars and keloids. *Aesthetic Plast Surg*, 11(1): 29-32.

(P)

- 98) ***Palmieri, B.; Gozzi, G and Palmieri, G.(1995):*** Vitamin E added silicone gel sheets for treatment of hypertrophic scars and keloids. *Int. J. Dermatol* ;34:506-9.

## (Q)

- 99) ***Quinn, J.V. (1998):*** Tissue Adhesives in Wound Care. Hamilton, Ont. B.C. Decker, Inc. *J. Am. Acad. Dermatol*, 30: 506-7.

## (R)

- 100) ***Reish ,RG and Eriksson E. (2008):*** Scar treatments: preclinical and clinical studies. *J. Am. Coll. Surg.* 206:719–30.
- 101) ***Reno, F . (2003):*** In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars. *Wound Repair.Regen.* 11:331–6.
- 102) ***Robert, H.; Demling, M.D. and Leslie-DeSanti, R.N. (2001):*** The anabolic Steroid, oxandrolone, reverses the wound healing impairment in corticosteroid-dependent burn and wound patients. *Wounds*, 13(5):203.
- 103) ***Robert, R.; Meyer, W. and Bishop, S. (1999):*** Disfiguring burn scars and adolescent self esteem. *Burns*, 25(7):581-5.
- 104) ***Robles DT, Berg D. (2007):*** Abnormal wound healing: keloids. *Clin. Dermatol.* 25:26–32.

- 105) **Rockwell, W.B.; Cohen, I.K. and Ehrlich, H.P. (1989):** Keloids and hypertrophic scars: a comprehensive review. *Plast Reconstr Surg*, 84(5):827-37.
- 106) **Romo, T. and Pearson, J.M. (2005):** Wound Healing, Skin. *The International Journal of Biochemistry & Cell Biology* 30 (9): 1019–1030. PMID 9785465.
- 107) **Rosenberg, L. and de la Torre J. (2006):** Wound Healing, Growth Factors. *Science*, 325: 612-616.doi:10.1126/science.
- 108) **Ruszczak, Z. (2003):** Effect of collagen matrices on dermal wound healing. *Advanced Drug Delivery Reviews*, 55(12): 1595–1611.

(S)

- 109) **Sandeman, S.R.; Allen, M.C.; Liu, C.; Faragher, R.G.A. and Lloyd A.W. (2000):** Human keratocyte migration into collagen gels declines with in vitro ageing. *Mechanisms of Ageing and Development*, 119(3): 149-157.
- 110) **Santoro, M.M. and Gaudino, G. (2005):** Cellular and molecular facets of keratinocyte reepithelization during wound healing. *Experimental Cell Research*, 304 (1): 274-286.
- 111) **Saray, Y and Gulen, AT.(2005):** Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: A preliminary study. *Int. J. Dermatol.* ;44:777-84.
- 112) **Shaffer ,JJ.;Taylor, SC and Cook-Bolden ,F.(2002)::** Keloidal scars: a review with a critical look at therapeutic options. *J. Am. Acad.Dermatol.*, 46:S63-97.

- 
- 113) **Shen, Y.C.; Chen, C.F. and Wang, S.Y. (1999):** Impediment to calcium influx and reactive oxygen production accounts for the inhibition of neutrophil Mac-1 Up-regulation and adhesion by tetrandrine, *Mol Pharmacol*, 55(1):186-93.
- 114) **Shih, PY.; Chen, HH.; Chen ,CH.; Hong, HS and Yang, CH.(2008):** Rapid recurrence of keloid after pulse dye laser treatment. *Dermatol Surg* ;34:1124-7.
- 115) **Skaria,A.M.(2004):** *Dermatology* 2004;209:71.
- 116) **Slemp, A and Kirschner RE. (2006):** Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. *Curr.Opin. Pediatr.* 18:396–402.
- 117) **Son, H.J.; Bae, H.C.; Kim, H.J.; Lee, D.H.; Han, D.W.; and Park, J.C. (2005):** Effects of  $\beta$ -glucan on proliferation and migration of fibroblasts. *Current Applied Physics*, 5(5): 468-471.
- 118) **Song, G.; Nguyen, DT; Pietramaggiori, G.; Scherer, S.; Chen, B.; Zhan, Q and Yannas, IV. (2010).** "Use of the parabiotic model in studies of cutaneous wound healing to define the participation of circulating cells". *Wound repair and regeneration : official publication of the Wound Healing Society and the European Tissue Repair Society* 18 (4): 426-432. doi:10.1111/j.1524-475X.2010.00595.x. PMC 2935287.
- 119) **Sorensen, O.E.; Thapa, D.R. and Roupé, K.M. (2006):** Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. *J.C.I.*, 116(7): 1878-85.
- 120) **Speranza ,G.; Sultanem, K and Muanza ,T.(2008):** Descriptive study of patients receiving excision and radiotherapy for keloids. *Int. J. Radiat. Oncol. Biol. Phys.*;71:1465-9.
-

- 121) **Stadelmann, W.K.; Digenis, A.G. and Tobin, G.R. (1998):** Physiology and healing dynamics of chronic cutaneous wounds. The American Journal of Surgery, 176 (2): 26S-38S.
- 122) **Stepien, O.; Zhang, Y.; Zhu, D. and Marche, P. (2002):** Dual mechanism of action of amlodipine in human vascular smooth muscle cells, J. Hypertens, 20(1):95-102.
- 123) **Stout, R.D., Watkins, S.K and Suttles, J.( 2009):** Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J. Leukoc. Biol. 86, 1105–1109.
- 124) **Sturgill, M.G and Seibold ,J.R. (1998):** Rational use of calcium-channel antagonists in Raynaud's phenomenon, Curr Opin Rheumatol 10(6):584-8, 1998.
- 125) **Subedi, N and Roberts, F.(2009):.** Radiotherapy treatment of keloid scars and other benign conditions: Is there a need for a database of patients treated? Br. J. Dermatol.;161:194-5.
- 126) **Swada, Y. and Sone, K. (1990):** Treatment of scars and keloids with a cream containing silicone oil. Br. J. Plast. Surg, 43: 683-8.
- 127) **Swirski, F.K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V.,et al (2009):** Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612–616.

- 128) **Tammela, T., Zarkada, G., Wallgard, E., Murtomaki, A., Suchting, S., Wirzenius, M. and Waltari, M. ( 2008):** Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. *Nature* 454, 656–660.
- 129) **Theoret ,C.L. (2004):**Update on wound repair. *Clinical Techniques in Equine Practice* 3 (2): 110-122.
- 130) **Thomas, A. (2002):** Scars and keloids. *B.M.J*; 328: 1329.
- 131) **Thomas, A. (2004):** The patient and observer scar assessment scale: A reliable and feasible tool for scar evaluation. *Plast Reconstr Surg*, 113(7): 1966.
- 132) **Thompson, A.E.; Shea ,B and Welch, V.(2001):** Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis, *Arthritis Rheum* 2001 Aug;44(8):1841-7.
- 133) **Tsao, S.S.; Dover, J.S.; Arndt, K.A. et al. (2002):** Scar management: keloid, hypertrophic, atrophic and acne scars. *Semin Cutan.. Meet Surg*, 21(1):46-75.

(V)

- 134) **Viani, GA.; Stefano, EJ.; Afonso ,SL and De Fendi, LI.(2009):** Postoperative strontium-90 brachytherapy in the prevention of keloids: Results and prognostic factors. *Int. J. Radiat. Oncol. Biol. Phys.* ;73:1510-6.

(W)

- 135) **Wada, Y.; Kato, S.; Okamoto, K.; et al. (2001):** Diltiazem, a calcium antagonist, inhibits matrix metalloproteinase-1 (tissue collagenase) production and collagenolytic activity in human vascular smooth muscle cells, *Int. J. Mol Med*, 8(5):561-6.
- 136) **Weinzweig, N.; Lukash, F. and Weinzweig, J. (1999):** Topical and systemic calcium channel blockers in the prevention and treatment of microvascular spasm in a rat epigastric island skin flap model, *Am. Plast. Surg*, 42:320-326.
- 137) **Witte, M.B. and Barbul, A. (2002):** Role of nitric oxide in wound repair. *The American Journal of Surgery*, 183(4): 406-412.

## (Y)

- 138) **Yaron, H.S.; Micha, A. and Edmond, S. (2003):** Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids. *Plast. Reconstr. Surg*, 111(6): 1841-52.

## (Z)

- 139) **Zouboulis, C.C. and Orfanos, C.E. (2000):** Cryosurgical treatment. In: M. Harahab (ed.), *Surgical Techniques For Cutaneous Scar-Revision*. New York: Marcel Dekker, pp. 185.